Hypoglycemia as first presentation of presumed immune checkpoint inhibitor‐induced type 1 diabetes

We present a case of a 60‐year‐old male diagnosed with metastatic clear cell renal cell carcinoma who developed hypoglycemia during induction ipilimumab and nivolumab treatment. This was diagnosed as presumed type 1 diabetes mellitus secondary to immunotherapy.

Detalles Bibliográficos
Autores principales: Kamal, Rayyan Syed, Dean, Arleigh, Dutt, Hanna, Rajeh, Adnan, Fernandes, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485243/
https://www.ncbi.nlm.nih.gov/pubmed/37692147
http://dx.doi.org/10.1002/ccr3.7897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485243/
https://www.ncbi.nlm.nih.gov/pubmed/37692147
http://dx.doi.org/10.1002/ccr3.7897

Ejemplares similares